Category

PUBLICATIONS

Graviton
6
Oncology
12/2016

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

San Antonio Breast Cancer Symposium
Read More
natalia
6
Oncology
12/2016

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

EBioMedicine
Read More
Graviton
6
NASH
11/2016

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans

AASLD The Liver Meeting
Read More
Graviton
4
Oncology
11/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640

NCRI Cancer Conference
Read More
natalia
6
Oncology
09/2016

Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

Precison: Lung Cancer R&D Summit
Read More
natalia
6
Oncology
08/2016

DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

Journal of Cell Signaling
Read More
Graviton
4
Oncology
06/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting
Read More
Graviton
4
Oncology
04/2016

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

AACR Annual Meeting
Read More
Graviton
4
Oncology
04/2016

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

AACR Annual Meeting
Read More
Graviton
4
Oncology
03/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

International Congress on Targeted Anticancer Therapies
Read More